Want to see MREO full AI Analyst Report?
MREO Stock Chart & Stats
$0.34
-$0.02(-0.40%)
At close: 4:00 PM EST
$0.34
-$0.02(-0.40%)
Day’s Range― - ―
52-Week Range$0.20 - $3.05
Previous CloseN/A
Volume219.93K
Average Volume (3M)5.32M
Market Cap
$49.39M
Enterprise Value$13.26M
Total Cash (Recent Filing)$36.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Aug 18, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding159,618,600
10 Day Avg. Volume2,235,101
30 Day Avg. Volume5,322,455
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.62
Price to Sales (P/S)132.86
P/FCF Ratio-2.14
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue26.52
Enterprise Value/Gross Profit212.10
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$3.00Price Target Upside782.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$14.28M
Bulls Say, Bears Say
Bulls Say
Low LeverageZero reported debt provides durable financial flexibility for a clinical-stage biopharma. Low leverage reduces fixed interest burdens, lowers bankruptcy risk, and preserves capacity to support R&D and trials through equity or partnerships without immediate debt service constraints.
High Gross Margins On RevenueReported low-70% gross margins indicate structurally attractive unit economics for biologic/antibody products. If clinical programs succeed and scale, these margins support long-term profitability potential and efficient conversion of sales into funding for further R&D and commercialization.
Board/Management ContinuityReappointment of key directors signals governance continuity and steady leadership during multi-year clinical development. Stable board and executive continuity helps preserve institutional knowledge, sustain partner and investor relationships, and supports consistent long-term strategy execution.
Bears Say
Minimal RevenueTTM revenue of roughly $0.5M indicates the company is not yet generating meaningful commercial sales, leaving operations dependent on milestone, licensing or financing events. This structural lack of recurring revenue increases reliance on external capital to fund development.
Sustained Cash BurnPersistent operating and free cash outflows (~$27M TTM) constitute a durable drain on resources for a clinical-stage firm. Continued cash burn implies recurring capital raises or partner deals are needed within months to sustain trials, elevating execution and financing risk over the medium term.
Large Losses & Declining EquityHeavy net losses (~$35.7M TTM) combined with a shrinking equity base materially reduce the company's capital cushion. This trend weakens the ability to absorb setbacks, makes future raises more dilutive or costly, and heightens long-term viability risk absent successful partnering or product milestones.
Mereo Biopharma Group Plc News
MREO FAQ
What was Mereo Biopharma’s price range in the past 12 months?
Mereo Biopharma lowest stock price was $0.20 and its highest was $3.05 in the past 12 months.
What is Mereo Biopharma’s market cap?
Mereo Biopharma’s market cap is $49.39M.
When is Mereo Biopharma’s upcoming earnings report date?
Mereo Biopharma’s upcoming earnings report date is Aug 18, 2026 which is in 45 days.
How were Mereo Biopharma’s earnings last quarter?
Mereo Biopharma released its earnings results on May 12, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.001.
Is Mereo Biopharma overvalued?
According to Wall Street analysts Mereo Biopharma’s price is currently Undervalued.
Does Mereo Biopharma pay dividends?
Mereo Biopharma does not currently pay dividends.
What is Mereo Biopharma’s EPS estimate?
Mereo Biopharma’s EPS estimate is >-0.01.
How many shares outstanding does Mereo Biopharma have?
Mereo Biopharma has 159,618,600 shares outstanding.
What happened to Mereo Biopharma’s price movement after its last earnings report?
Mereo Biopharma reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went up 1.653%.
Which hedge fund is a major shareholder of Mereo Biopharma?
Currently, no hedge funds are holding shares in MREO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mereo Biopharma Group Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (782.35% Upside)
$3.00 (782.35% Upside)
Blogger Sentiment
Bullish
MREO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 517.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.36%
12-Months-Change
Fundamentals
Return on Equity
-81.25%
Trailing 12-Months
Asset Growth
-40.55%
Trailing 12-Months
Company Description
Mereo Biopharma
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
MREO Stock 12 Month Forecast
Average Price Target
$3.00
▲(782.35% Upside)
Technical Analysis
Ownership Overview
0.81%
Insiders
0.09% Mutual Funds
37.27% Other Institutional Investors
61.74% Public Companies and
Individual Investors